WO2000041481A2 - Arzneiformen mit gesteuerter freisetzung, enthaltend gut wasserlösliche wirkstoffe - Google Patents
Arzneiformen mit gesteuerter freisetzung, enthaltend gut wasserlösliche wirkstoffe Download PDFInfo
- Publication number
- WO2000041481A2 WO2000041481A2 PCT/EP2000/000053 EP0000053W WO0041481A2 WO 2000041481 A2 WO2000041481 A2 WO 2000041481A2 EP 0000053 W EP0000053 W EP 0000053W WO 0041481 A2 WO0041481 A2 WO 0041481A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dosage form
- water
- controlled release
- active ingredient
- methacrylic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- the present invention relates to drug forms with controlled release, containing active ingredients with a water solubility according to USP of up to 30 in a matrix based on acrylate polymers, which are obtained by melt extrusion.
- the object of the present invention was to find pharmaceutical forms which enable the controlled release of readily water-soluble active substances.
- readily water-soluble active ingredients are those which have a water solubility according to USP 23 of 1 to 10 (easily soluble) or 10 to 30 (soluble), preferably less than 1 (very easily soluble).
- the numbers refer to how many parts of solvent are required per part of the substance to be dissolved.
- Preferred active ingredients are metoprolol and its salts, particularly preferably metoprolol tartrate.
- the active ingredients are homogeneously dispersed in a matrix based on acrylate polymers or dissolved in the form of a solid solution.
- the active substance is preferably present in the matrix in X-ray amorphous form.
- Solid solutions of the active ingredient are particularly preferably obtained.
- acrylate polymers are particularly swellable polymers of the Eudragit ® type.
- Suitable polymers are, for example, methacrylic acid copolymers (Eudragit L types) such as methacrylic acid-ethyl acrylate 1: 1 copolymers M 250,000, methacrylic acid-methyl methacrylate 1: 1 copolymers M 135,000, methacrylic acid-methyl methacrylate 1: 2 copolymers M 135,000 or dimethylaminoethyl methacrylic lat copolymers (Eudragit E) such as poly (butyl methacrylate (2-dimethylaminoethyl) methacrylate) -1: 2: 1 M 150,000.
- Medragit L types such as methacrylic acid-ethyl acrylate 1: 1 copolymers M 250,000, methacrylic acid-methyl methacrylate 1: 1 copolymers M 135,000, methacrylic acid-methyl methacrylate 1: 2
- the amounts of active ingredient and acrylate polymers are chosen so that the dosage forms contain 1 to 50% by weight, preferably 10 to 30% by weight, of active ingredient.
- Formulations containing 1 to 80, preferably 10 to 40% by weight Eudragit RL and 1 to 50, preferably 5 to 20% by weight Eudragit RS are particularly suitable.
- polymers can be contained in the matrix, for example homo- or copolymers of N-vinylpyrrolidone such as povidone or copovidone 6: 4 or preferably cellulose ethers such as
- Hydroxypropylmethyl cellulose ethyl cellulose or hydroxypropyl cellulose.
- auxiliaries can be added for additional retardation.
- hydrophobizing auxiliaries such as lipids or their salts, for example stearic acid, palmitic acid, hydrogenated ricinoleic acid or similar, preferably magnesium stearate.
- preparations can also contain other customary pharmaceutical auxiliaries in the amounts customary for this, for example stabilizers, antioxidants, colorants, flavorings, fillers or stabilizers such as, for example, highly disperse silicon dioxide or lubricants.
- other customary pharmaceutical auxiliaries for example stabilizers, antioxidants, colorants, flavorings, fillers or stabilizers such as, for example, highly disperse silicon dioxide or lubricants.
- the preparations according to the invention are produced by mixing the components using shear forces and supplying thermal energy. Mixing is preferably carried out in a single-screw or multi-screw extruder, particularly preferably in a twin-screw extruder. A melt of the mixture components is generated by supplying thermal energy. This is usually done by heating the extruder jacket to temperatures in the range from 50 to 180, preferably 80 to 130 ° C. The active ingredient can be mixed with the other components before or after the melting of the polymeric binder. The melts are solvent-free. This means that no water or organic solvents are added.
- the molten mixture of the components is conveyed by the screw movement in the direction of the extruder outlet, which preferably consists of a nozzle. After extrusion through the nozzle, the still plastic mass is shaped into suitable medicinal forms.
- Suitable dosage forms are preferably tablets, in particular bolus tablets, lenticular tablets or oblong tablets.
- Tablets are preferably produced in accordance with the process described in EP-A 240 906 by passing the still plastic strand between two oppositely driven rollers with mutually opposite recesses in the roller shell. By appropriately choosing the shape of these recesses, tablets with score lines can also be obtained. Granules or pellets can be obtained by cold cutting or, preferably, by hot cutting.
- the dosage forms can additionally be provided with coatings known per se which have no influence on the release behavior.
- the combination according to the invention of the melt extrusion process with a corresponding formulation based on acrylate polymers can also be used to produce pharmaceutical forms with controlled release for highly water-soluble active ingredients.
- the terms of their release bioequivalent to the metoprolol succinate-containing product market Toprol-ZOK ® are.
- the tablets were produced by extrusion of the mixtures listed in the table below in a co-rotating twin-screw extruder of the type ZKS-40 from Werner & Pfleiderer and subsequent calendering to oblong tablets with a tablet weight of 500 mg according to that in EP-A 240 906 described methods. Temperature profile of the extruder:
- Polyethylene glycol 6000 1.61 finely divided silica 0.15
- the in vitro release was determined according to USP 23 in a paddle apparatus at 100 rpm in artificial intestinal juice at pH 6.8, no change, 24 h.
- a tablet according to Example 11 was administered as a single dose to eight healthy male volunteers in the fasting state.
- Beloc-ZOK (with the same amount of free metoprolol base) was administered as the reference substance under the same conditions.
- the geometric mean of the plasma concentration is shown in FIG. The squares denote the extrudate form according to the invention, the diamonds the reference substance.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002359381A CA2359381A1 (en) | 1999-01-14 | 2000-01-07 | Medicament forms having controlled release and containing active substances which easily dissolve in water |
JP2000593105A JP2002534443A (ja) | 1999-01-14 | 2000-01-07 | 十分に水溶性の作用物質を含有している制御された放出を有する剤形 |
EP00904879A EP1140030A2 (de) | 1999-01-14 | 2000-01-07 | Arzneiformen mit gesteuerter freisetzung, enthaltend gut wasserlösliche wirkstoffe |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19901040A DE19901040A1 (de) | 1999-01-14 | 1999-01-14 | Arzneiformen mit gesteuerter Freisetzung, enthaltend gut wasserlösliche Wirkstoffe |
DE19901040.4 | 1999-01-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000041481A2 true WO2000041481A2 (de) | 2000-07-20 |
WO2000041481A3 WO2000041481A3 (de) | 2000-09-28 |
Family
ID=7894143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/000053 WO2000041481A2 (de) | 1999-01-14 | 2000-01-07 | Arzneiformen mit gesteuerter freisetzung, enthaltend gut wasserlösliche wirkstoffe |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1140030A2 (de) |
JP (1) | JP2002534443A (de) |
CA (1) | CA2359381A1 (de) |
DE (1) | DE19901040A1 (de) |
WO (1) | WO2000041481A2 (de) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007085024A2 (en) * | 2006-01-21 | 2007-07-26 | Abbott Gmbh & Co. Kg | Dosage form and method for the delivery of drugs of abuse |
WO2008011595A2 (en) * | 2006-07-21 | 2008-01-24 | Lab International Srl | Hydrophobic abuse deterrent delivery system |
JP2010100641A (ja) * | 2000-12-26 | 2010-05-06 | Lab Servier | イバブラジン制御放出のための熱成形可能な固形医薬組成物 |
US9226907B2 (en) | 2008-02-01 | 2016-01-05 | Abbvie Inc. | Extended release hydrocodone acetaminophen and related methods and uses thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8481565B2 (en) | 2004-12-27 | 2013-07-09 | Eisai R&D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5073379A (en) * | 1988-09-07 | 1991-12-17 | Basf Aktiengesellschaft | Continuous preparation of solid pharmaceutical forms |
EP0661045A1 (de) * | 1992-09-18 | 1995-07-05 | Yamanouchi Pharmaceutical Co. Ltd. | Hydrogelzubereitung mit verzögerter freisetzung |
WO1996029061A1 (de) * | 1995-03-21 | 1996-09-26 | Basf Aktiengesellschaft | Verfahren zur herstellung von wirkstoffzubereitungen in form einer festen lösung des wirkstoffs in einer polymermatrix sowie mit diesem verfahren hergestellte wirkstoffzubereitungen |
-
1999
- 1999-01-14 DE DE19901040A patent/DE19901040A1/de not_active Withdrawn
-
2000
- 2000-01-07 CA CA002359381A patent/CA2359381A1/en not_active Abandoned
- 2000-01-07 EP EP00904879A patent/EP1140030A2/de not_active Withdrawn
- 2000-01-07 JP JP2000593105A patent/JP2002534443A/ja active Pending
- 2000-01-07 WO PCT/EP2000/000053 patent/WO2000041481A2/de not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5073379A (en) * | 1988-09-07 | 1991-12-17 | Basf Aktiengesellschaft | Continuous preparation of solid pharmaceutical forms |
EP0661045A1 (de) * | 1992-09-18 | 1995-07-05 | Yamanouchi Pharmaceutical Co. Ltd. | Hydrogelzubereitung mit verzögerter freisetzung |
WO1996029061A1 (de) * | 1995-03-21 | 1996-09-26 | Basf Aktiengesellschaft | Verfahren zur herstellung von wirkstoffzubereitungen in form einer festen lösung des wirkstoffs in einer polymermatrix sowie mit diesem verfahren hergestellte wirkstoffzubereitungen |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010100641A (ja) * | 2000-12-26 | 2010-05-06 | Lab Servier | イバブラジン制御放出のための熱成形可能な固形医薬組成物 |
WO2007085024A2 (en) * | 2006-01-21 | 2007-07-26 | Abbott Gmbh & Co. Kg | Dosage form and method for the delivery of drugs of abuse |
WO2007085024A3 (en) * | 2006-01-21 | 2008-03-13 | Abbott Gmbh & Co Kg | Dosage form and method for the delivery of drugs of abuse |
WO2008011595A2 (en) * | 2006-07-21 | 2008-01-24 | Lab International Srl | Hydrophobic abuse deterrent delivery system |
WO2008011596A2 (en) * | 2006-07-21 | 2008-01-24 | Lab International Srl | Hydrophilic abuse deterrent delivery system |
WO2008011596A3 (en) * | 2006-07-21 | 2008-11-13 | Lab Internat Srl | Hydrophilic abuse deterrent delivery system |
WO2008011595A3 (en) * | 2006-07-21 | 2008-11-13 | Lab Internat Srl | Hydrophobic abuse deterrent delivery system |
US9226907B2 (en) | 2008-02-01 | 2016-01-05 | Abbvie Inc. | Extended release hydrocodone acetaminophen and related methods and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2002534443A (ja) | 2002-10-15 |
EP1140030A2 (de) | 2001-10-10 |
CA2359381A1 (en) | 2000-07-20 |
WO2000041481A3 (de) | 2000-09-28 |
DE19901040A1 (de) | 2000-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69532415T3 (de) | Schmelzextrudierte oral verabreichbare opioidformulierungen | |
DE60027608T2 (de) | Mesalazine enthaltende pharmazeutische Zusammensetzungen mit gesteuerter Freisetzung | |
EP0544144B1 (de) | Feste pharmazeutische Retardform | |
EP1001757B1 (de) | Schnell wirksames analgeticum | |
EP0864326B1 (de) | Mehrphasige wirkstoffhaltige Zubereitungsformen | |
EP0760654B1 (de) | Verfahren zur herstellung von wirkstoffzubereitungen in form einer festen lösung des wirkstoffs in einer polymermatrix | |
EP0181515B1 (de) | Verfahren zur Herstellung einer wässrigen Überzugsmitteldispersion und ihre Verwendung zum Überziehen von Arzneimitteln | |
DE69007623T2 (de) | Arzneimittel mit verzögerter wirkstofffreigabe. | |
WO2000057854A2 (de) | Mechanisch stabile pharmazeutische darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive substanzen | |
DE10026699A1 (de) | Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage | |
EP0596203A1 (de) | Wirkstoffe und wasserlösliche Polymeren enthaltende Zubereitungen in Form fester Teilchen | |
DE19509805A1 (de) | Transparente, schnell freisetzende Zubereitungen von nichtsteroidalen Analgetica | |
EP0485840B1 (de) | Orale Arzneiform und Überzugsmittel, enthaltend ein im Colon abbaubares Polysaccharid | |
WO2001000175A1 (de) | Mechanisch stabile pharmazeutische darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive substanzen | |
DE19842753A1 (de) | Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung | |
WO2000064415A1 (de) | Verfahren zur herstellung einer wasserunlöslichen amorphen oder teilamorphen retardmatrix | |
EP1140030A2 (de) | Arzneiformen mit gesteuerter freisetzung, enthaltend gut wasserlösliche wirkstoffe | |
DE69008107T2 (de) | Zubereitung mit verzögerter Freigabe eines Hydrochlorids eines basischen Arzneistoffs. | |
EP0876141B1 (de) | Zubereitungen nichtsteroidaler analgetika | |
EP1142571B1 (de) | Verfahren zur Herstellung von festen Kreatin-Dosierungsformen und dadurch erhältliche Dosierungsformen | |
DE19800927A1 (de) | Verfahren zur Herstellung von festen Dosierungsformen | |
EP1189614B1 (de) | Feste paroxetin enthaltende zubereitungen | |
EP0998919A2 (de) | Feste Dosierungsform mit copolymerem Bindemittel | |
DE19724181A1 (de) | Multiple-unit-retard-Zubereitungen und Verfahren zu ihrer Herstellung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): BR CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): BR CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 593105 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref document number: 2359381 Country of ref document: CA Ref country code: CA Ref document number: 2359381 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000904879 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000904879 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09868917 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000904879 Country of ref document: EP |